Boston Scientific Subsidiaries Barred From Selling Multiple Drug-Eluting Stent Lines In Germany
This article was originally published in The Gray Sheet
Executive Summary
A German court had previously blocked Boston Scientific’s German subsidiary from selling drug-eluting stents affected by OrbusNeich’s patent suit; the new injunction closes a loophole, preventing any Boston Scientific subsidiary from selling the devices in Germany.
You may also be interested in...
News In Brief
Maquet acquires LAAx. OrbusNeich says it called the cops on Boston Scientific. More news
News In Brief
Two deputy commissioners depart FDA. NICE takes over U.K. program to encourage adoption of new medical technologies. More news.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.